Learn more

SIGMA TAU IND FARMACEUTICHE RIUNITE S P A

Overview
  • Total Patents
    124
  • GoodIP Patent Rank
    228,526
About

SIGMA TAU IND FARMACEUTICHE RIUNITE S P A has a total of 124 patent applications. Its first patent ever was published in 2000. It filed its patents most often in Australia, Montenegro and Brazil. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are ANGIOGENE PHARM LTD, HORMOS MEDICAL CORP and SIGMA TAU IND FARMACEUTI.

Patent filings in countries

World map showing SIGMA TAU IND FARMACEUTICHE RIUNITE S P As patent filings in countries
# Country Total Patents
#1 Australia 87
#2 Montenegro 12
#3 Brazil 8
#4 Canada 7
#5 Ukraine 4
#6 Chile 2
#7 Israel 2
#8 Hong Kong 1
#9 United States 1

Patent filings per year

Chart showing SIGMA TAU IND FARMACEUTICHE RIUNITE S P As patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Pisano Claudio 23
#2 Tinti Maria Ornella 14
#3 Vesci Loredana 14
#4 Koverech Aleardo 14
#5 Carminati Paolo 12
#6 Giannini Giuseppe 12
#7 Cabri Walter 8
#8 Giannessi Fabio 7
#9 Cavazza Claudio 6
#10 Marzi Mauro 6

Latest patents

Publication Filing date Title
AU2012311640A1 New thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments
CA2787470A1 Combination composition, comprising as active ingredients l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insufficiency
BRPI0922155A2 use of alkanoyl l-carnitine in combination with chemotherapeutic agents for cancer treatment
AU2009324183A1 Use of alkanoyl L-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms
AU2009278317A1 Long-term treatment of symptomatic heart failure
CA2694391A1 Oxidized avidin with high residency time in the treated tissues
AU2008225833A1 Amide compounds and their use as antitumor agents
AU2007214359A1 Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds
AU2006265248A1 Use of L-carnitine or of alkanoyl L-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye-drops
AU2006222315A1 Chimeric recombinant antigens of Toxoplasma gondii
AU2006220097A1 Derivatives of aminobutanoic acid inhibiting CPT
AU2005318227A1 Stereoselective process and crystalline forms of a camptothecin
AU2003288546A1 Use of alpha-phenylthiocarboxylic and alpha-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity
AU2003288534A1 Variously substituted derivatives of guanidine, and their use as medicines with anti-diabetes and/or anti-obesity activity
AU2003253258A1 Fluoro-alkyl-cyclopeptide derivatives having anti-integrin activity
AU2002326146B2 Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine A2a receptor and their use as medicaments
AU2002326144B2 Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities
AU2002324328B2 Use of long pentraxin PTX3 for treating female infertility
AU2001277686B2 Use of fibrates for the preparation of a medicament useful in the treatment of congestive heart failure
AU2001277687B2 Process for the preparation of 9-amino substituted 9,10-dihydropyrrolo [2,1-B][1,3]benzotiazepines